Pharmaceutical company Moderna Inc (NASDAQ: MRNA) announced on Tuesday that it has achieved successful Phase 3 trial results for mRNA-1283, its next-generation COVID-19 vaccine. Compared to its licensed vaccine mRNA-1273.222, mRNA-1283 induces a stronger immune response against SARS-CoV-2, particularly in individuals over 65.
The NextCOVE trial involved over 11,400 participants aged 12 and above across the US, UK and Canada. mRNA-1283 demonstrates a similar safety profile to Moderna's approved COVID-19 vaccines.
mRNA-1283's storage, shelf life, and pre-filled syringe presentation could ease healthcare provider burden and enhance accessibility in various settings. Detailed trial data will be presented at Moderna's Vaccines Day event on 27 March 2024.
Moderna's mRNA platform has revolutionised medicine development, delivering rapid and efficient solutions for infectious diseases, immuno-oncology, rare diseases and autoimmune conditions. The company's mission is to create a healthier future through innovative mRNA medicines.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation